High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1108-1113

  Wickramasinghe, Nimal H ^a   Xu, Li ^a,b   Eustace, Andrew ^a   Shabir, Sahida ^a   Saluja, Tranprit ^c   Hawkey, Peter M ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Clonal spread; CTX M 15; Ethnicity; ST131

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; METALLO BETA LACTAMASE;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; ESCHERICHIA COLI; FECES ANALYSIS; GENERAL PRACTICE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; OUTPATIENT; UNITED KINGDOM;

AMBULATORY CARE; BACTERIOLOGICAL TECHNIQUES; BETA-LACTAMASES; CARRIER STATE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER ANALYSIS; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; GENERAL PRACTICE; GENOTYPE; GREAT BRITAIN; HUMANS; POPULATION GROUPS; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 84859592534     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks018     Document Type: Article

References (33)

1. Nordmann P, Poirel L, Walsh TR et al. The emerging NDM carbapenemases. Trends Microbiol 2011; 19: 588-95.
2. White AR. The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. J Antimicrob Chemother 2008; 62 Suppl 2: ii3-14.
3. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
4. Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 2008; 14 Suppl 1: 159-65.
5. Hawser S, Hoban D, Bouchillon S et al. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011; 30: 173-9.
6. Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628-33.
7. Pitout JD, Gregson DB, Campbell L et al. Molecular characteristics of extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53: 2846-51.
8. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35: 316-21.
9. Andrews JM. BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother 2008; 62: 256-78.
10. CTX-M genes by multiplex PCR assay. J Med Microbiol 2005; 54: 1183-7.
11. Xu L, Evans J, Ling T et al. Rapid genotyping of CTX-M extended-spectrum β-lactamases by denaturing high-performance liquid chromatography. Antimicrob Agents Chemother 2007; 51: 1446-54.
12. Xu L, Shabir S, Bodah T et al. Regional survey of CTX-M-type extended-spectrum β-lactamases among Enterobacteriaceae reveals marked heterogeneity in the distribution of the ST131 clone. J Antimicrob Chemother 2011; 66: 505-11.
13. Tartof SY, Solberg OD, Manges AR et al. Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing. J Clin Microbiol 2005; 43: 5860-4.
14. MLST Databases. 2011. University College Cork, Ireland. http://mlst.ucc.ie/mlst/dbs/Ecoli (24 December 2011, date last accessed).
15. OriginsInfo. 2011. http://www.originsinfo.eu (24 December 2011, date last accessed).
16. Webber R. Using names to segment customers by cultural, ethnic or religious origin. J Direct Data Digital Market Pract 2007; 8: 226-42.
17. Evans JT, Gardiner S, Smith EG et al. Global origin of Mycobacterium tuberculosis in the Midlands, UK. Emerg Infect Dis 2010; 16: 542-5.
18. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to " critically important" antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501-6.
19. Tangden T, Cars O, Melhus A et al. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum β-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54: 3564-8.
20. Tham J, Odenholt I, Walder M et al. Extended-spectrum β-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010; 42: 275-80.
21. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 Suppl 1: i3-10.
22. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23: 320-6.
23. Karim A, Poirel L, Nagarajan S et al. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201: 237-41.
24. Ensor VM, Shahid M, Evans JT et al. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006; 58: 1260-3.
25. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81.
26. Johnson JR, Johnston B, Clabots C et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51: 286-94.
27. Lau SH, Kaufmann ME, Livermore DM et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 β-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother 2008; 62: 1241-4.
28. Peirano G, Richardson D, Nigrin J et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extendedspectrum-β-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother 2010; 54: 1327-30.
29. Valverde A, Grill F, Coque TM et al. High rate of intestinal colonization with extended-spectrum-β-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008; 46: 2796-9.
30. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
31. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
32. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36 Suppl 3: S8-14.
33. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.